| Sodium-Glucose Cotransporter 2 Inhibitor Use Among Individuals Age | ClinicoEconomics and Outcomes Research | |
| Sodium-Glucose Co-transporter-2 Inhibitors in Heart Failure with Preserved Ejection Fraction: A Breakthrough in Improvement of Clinical Outcomes? | European Medical Journal (Chelmsford, England) | |
| ROLE AND PLACE OF DAPAGLIFLOZIN IN THE MANAGEMENT OF 2nd TYPE DIABETES: FROM THEORY TO PRACTICE | Meditsinskiy Sovet | 2017 |
| The Cardiovascular Benefits Associated with the Use of Sodium-Glucose Cotransporter 2 Inhibitors - Real-World Data | European Endocrinology | 2018 |
| A novel valuation model for medical intervention development based on progressive dynamic changes that integrates Health Technology Assessment outcomes with early-stage innovation and indication-specific clinical success rates | Journal of Innovation and Entrepreneurship | 2020 |
| Cardiovascular safety outcomes of once-weekly GLP-1 receptor agonists in people with type 2 diabetes | Journal of Clinical Pharmacy and Therapeutics | 2020 |
| SGLT1 inhibition boon or bane for diabetes-associated cardiomyopathy | Fundamental and Clinical Pharmacology | 2020 |
| Effects of Sodium-glucose Cotransporter 2 Inhibitors on Amputation, Bone Fracture, and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus Using an Alternative Measure to the Hazard Ratio | Clinical Drug Investigation | 2019 |
| Management of Diabetes Mellitus | Contemporary Cardiology | 2019 |
| Effect of empagliflozin beyond glycemic control: Cardiovascular benefit in patients with type 2 diabetes and established cardiovascular disease | Revista Portuguesa De Cardiologia | 2019 |
| Effect of empagliflozin beyond glycemic control: Cardiovascular benefit in patients with type 2 diabetes and established cardiovascular disease | Revista Portuguesa De Cardiologia (English Edition) | 2019 |
| Leptin, cardiovascular diseases and type 2 diabetes mellitus | Acta Pharmacologica Sinica | 2018 |
| Comparison of Oral Antidiabetic Drugs as Add-On Treatments in Patients with Type 2 Diabetes Uncontrolled on Metformin: A Network Meta-Analysis | Diabetes Therapy | 2018 |
| Clinical assessment and treatment of diabetes in patients with chronic kidney disease | Revista Clínica Espanõla | 2018 |
| Cardiovascular Safety of Empagliflozin Versus Dipeptidyl Peptidase-4 (DPP-4) Inhibitors in Type 2 Diabetes: Systematic Literature Review and Indirect Comparisons | Diabetes Therapy | 2018 |
| SGLT-2 Inhibitors and Cardiovascular Risk: An Analysis of CVD-REAL | Journal of the American College of Cardiology | 2018 |
| Antihyperglycemic Medications and Impact on Cardiovascular Outcomes: A Review of Current Evidence | Pharmacotherapy | 2018 |
| Empagliflozin Ammeliorates High Glucose Induced-Cardiac Dysfuntion in Human iPSC-Derived Cardiomyocytes | Scientific Reports | 2018 |
| Improving postprandial hyperglycemia in patients with type 2 diabetes already on basal insulin therapy: Review of current strategies | Journal of Diabetes | 2018 |
| When metformin is not enough: Pros and cons of SGLT2 and DPP-4 inhibitors as a second line therapy | Diabetes/Metabolism Research and Reviews | 2018 |
| Effect of glucose-lowering therapies on heart failure | Nature Reviews Cardiology | 2018 |
| Clinical assessment and treatment of diabetes in patients with chronic kidney disease | Revista Clinica Espanola | 2018 |
| Glycemic control of type 2 diabetes mellitus across stages of renal impairment: information for primary care providers | Postgraduate Medicine | 2018 |
| Heart failure hospitalization risk associated with use of two classes of oral antidiabetic medications: an observational, real-world analysis | Cardiovascular Diabetology | 2017 |
| Effects of antidiabetic drugs on the incidence of macrovascular complications and mortality in type 2 diabetes mellitus: a new perspective on sodium-glucose co-transporter 2 inhibitors | Annals of Medicine | 2017 |
| Cardiovascular Effects of Glucose-lowering Therapies for Type 2 Diabetes: New Drugs in Perspective | Clinical Therapeutics | 2017 |
| Cardiovascular outcomes with sodium-glucose cotransporter-2 inhibitors in patients with type II diabetes mellitus: A meta-analysis of placebo-controlled randomized trials | International Journal of Cardiology | 2017 |
| Cardiovascular disease prevention strategies for type 2 diabetes mellitus | Expert Opinion on Pharmacotherapy | 2017 |
| Cardiovascular safety outcomes of new antidiabetic therapies | American Journal of Health-System Pharmacy | 2017 |
| Comparative Effectiveness for Glycemic Control in Older Adults with Diabetes | Current Geriatrics Reports | 2017 |
| Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitor: Comparing Trial Data and Real-World Use | Diabetes Therapy | 2017 |
| The use of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes and hypertension: a focus on African-American populations | Postgraduate Medicine | 2017 |
| A review on cardiovascular effects of newer hypoglycaemic medications | Annals of Medicine | 2017 |
| Therapeutic Considerations for Antihyperglycemic Agents in Diabetic Kidney Disease | Journal of the American Society of Nephrology: JASN | 2017 |
| Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors: Comparing Trial and Real World Use (Study Protocol) | Diabetes Therapy | 2017 |
| Cardioprotective effects of SGLT2 inhibitors are possibly associated with normalization of the circadian rhythm of blood pressure | Hypertension Research | 2017 |
| Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis | Cardiovascular Diabetology | 2016 |
| Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis | Diabetes, Obesity and Metabolism | 2016 |
| What Are We Learning from the FDA-Mandated Cardiovascular Outcome Studies for New Pharmacological Antidiabetic Agents? | Current Diabetes Reports | 2016 |
| Long-term maintenance of efficacy of dapagliflozin in patients with type 2 diabetes mellitus and cardiovascular disease | Diabetes, Obesity and Metabolism | 2016 |
